Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 170Neoplasm Metastasis 139Neoplasms 136Leukemia, Myeloid, Acute 133Colorectal Neoplasms 115Breast Neoplasms 115Melanoma 90Ovarian Neoplasms 88Prostatic Neoplasms 85Recurrence 83Multiple Myeloma 81Lung Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 71Pancreatic Neoplasms 70Myelodysplastic Syndromes 63Lymphoma, Non-Hodgkin 59Triple Negative Breast Neoplasms 53Glioma 53Stomach Neoplasms 49Endometrial Neoplasms 46Brain Neoplasms 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Lymphoma, Large B-Cell, Diffuse 45Carcinoma, Renal Cell 45Small Cell Lung Carcinoma 44Lymphoma, Follicular 40Lymphoma, B-Cell 40Carcinoma, Hepatocellular 40Sarcoma 39

Interventions

spartalizumab 1balstilimab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hemangiosarcoma × 90 days × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡